IS1. Mind and Body in the Patient with Depression: Clinical Implications of the Interrelationship Between Psychiatric, Cerebrovascular, and Cardiovascular Disease Supported by Forest Laboratories Inc.

A. Prefrontal Dysfunction in Geriatric Patients George S. Alexopoulos, M.D.

B. Neuropsychiatric Consequences of Stroke Robert G. Robinson, M.D.

C. Cardiovascular Disease and Depression: Cause, Effect, or Conundrum? Francois Lesperance, M.D.

D. Antidepressant Pharmacotherapy in the Elderly and Old-Old Carl Salzman, M.D.

E. Psychopharmacology in the Context of Comorbid Vascular Illness: Applying Knowledge of Drug Metabolism to Optimize Drug Therapy David J. Greenblatt, M.D.

IS2. Progress on Sexual Dysfunction: Prevalence, Classification, Assessment, Mechanisms, and Management Supported by U.S. Pharmaceuticals, Pfizer Inc.

A. Epidemiology, Classification, and Assessment of Sexual Dysfunction Anita L.H. Clayton, M.D.

B. Antidepressant-Induced Sexual Dysfunction Andrew A. Nierenberg, M.D.

C. Management of Antidepressant-Induced Sexual Dysfunction H. George Nurnberg, M.D.

D. Hormone-Replacement Therapy and Sexual Function Julia K. Warnock, M.D.

E. Erectile Dysfunction: Diagnosis and Treatment Matthew A. Menza, M.D.

IS3. Reproductive Psychiatry: An Update Supported by SmithKline Beecham Pharmaceuticals

A. Premenstrual Dysphoric Disorder: New Research Meir Steiner, M.D.

B. Mood Disorders in Pregnancy and Lactation: Treatment Issues Zachary N. Stowe, M.D.

C. Reproductive Psychiatry: An Update on Women’s Health Shaila Misri, M.D.

D. Mood, Hormones, and Menopause Catherine A. Roca, M.D.

IS4. The Many Faces of Psychosis Supported by Janssen Pharmaceutica and Research Foundation

A. The Genetic Epidemiology of Psychosis Kenneth S. Kendler, M.D.

B. Psychosis Associated with Major Depression J. Craig Nelson, M.D.

C. Psychosis Associated with Bipolar and Schizoaffective Disorders S. Nassir Ghaemi, M.D.

D. Psychosis Associated with Schizophrenia Prakash S. Masand, M.D.

E. Psychosis Associated with Dementia George T. Grossberg, M.D.

IS5. Norepinephrine and Depression in the Elderly Supported by Pharmacia & Upjohn Company Inc.

A. Epidemiology and Clinical Presentation of Depression in the Elderly Soo Borson, M.D.

B. The Importance of the Prefrontal Noradrenergic Systems in Depression, Alzheimer’s Disease, and Psychosis Kenneth L. Davis, M.D.

C. Significance of Anergia and Anhedonia as Symptoms of Depression: Biological and Pharmacological Perspectives Bruce G. Pollock, M.D.

D. Efficacy and Safety of Noradrenergic Antidepressants in the Elderly Alan F. Schatzberg, M.D.

E. Treatment Options for Medical and Psychiatric Comorbidity with Depression Dwight L. Evans, M.D.

IS6. Dopamine: Beyond Schizophrenia, Tools for Treatment Supported by Glaxo Wellcome Inc.

A. The Meso-Limbic Dopamine System in Motivation and Reward Roy Wise, Ph.D.

B. Smoking, Smoking Cessation, and Antidepressants Alexander H. Glassman, M.D.

C. Dopamine in the Treatment of Depression Maurizio Fava, M.D.

D. Direct and Indirect Modulation of Cortical Circuits Involved in Cognition Patricia Goldman-Rakic, Ph.D.

E. Dopamine in the Etiology and Treatment of ADHD F. Xavier Castellanos, M.D.

IS7. Schizophrenia: From Social Isolation to Social Reintegration Supported by Eli Lilly and Company

A. Impact of Early Identification and Treatment on First-Episode Schizophrenia Jeffrey A. Lieberman, M.D.

B. Cognitive Deficits and Everyday Functioning Richard S.E. Keefe, Ph.D.

C. Atypical Antipsychotic Agents: Expanding the Goals of Therapy to Improve Outcomes Richard G. Petty, M.D.

D. Improving Outcomes: Reintegration in Disadvantaged Populations Ralph Aquila, M.D.

E. Quality of Life and Economic Outcomes in Treatment Martin R.J. Knapp, Ph.D.